



Financial Tear Sheet

Corporate Profile

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

Primary IR Contact

Marianne M. Lambertson
Vice President, Corporate
Communications

Phone: 781-292-4273

E-mail:

mlambertson@verastem.com

Stock Performance

VSTM (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$4.44
Change (%)	▼ 0.17 (3.69%)
Volume	2,077,538
52 Week Low	\$2.77
Market Cap	\$327,633,567
Rolling EPS	-1.42
PE Ratio	N/A
Shares Outstanding	73,791,344



Data as of December 07, 2018 4:00 p.m. ET

Recent Headlines & Events

December 5, 2018 - 4:05 p.m.

[Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

December 4, 2018 - 7:00 a.m.

[Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting](#)

December 3, 2018 - 5:05 p.m.

[Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/04/18	CT ORDER
11/19/18	DEF 14A
11/09/18	PRE 14A
11/09/18	S-8

Corporate Governance

Robert Forrester, LL.B.	President/Chief Executive Officer
Dan Paterson	Chief Operating Officer
Steven Bloom	Chief Strategy Officer
Joseph Lobacki	Chief Commercial Officer
Jonathan Pachter, Ph.D.	Chief Scientific Officer
Hagop Youssoufian, MSc, M.D.	Head, Medical Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.